SEC Form 4 · accession 0001209191-18-016436

Ultragenyx Pharmaceutical Inc. · RARE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — See Remarks

Period of report

Mar 1, 2018

Accepted (ET)

Mar 5, 2018 · 4:21 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001515673

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	Mar 1, 2018	A	5,000	$0.00	A	16,921	D
Common Stock^F4	Mar 1, 2018	F	276	$48.43	D	16,645	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F5	$48.43	Mar 1, 2018	A	27,000	A	—	Mar 1, 2028	Common Stock	27,000	27,000	D

F1Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
F2Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F3Includes 38 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2017.
F4Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
F5On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

EVP of Translational Sciences and Chief Quality Officer